Results 221 to 230 of about 648,624 (244)
Some of the next articles are maybe not open access.
Cardiovascular Protection with Anti-hyperglycemic Agents
American Journal of Cardiovascular Drugs, 2019Diabetes mellitus is a major risk factor for cardiovascular (CV) disease. Conversely, CV disease is responsible for a majority of the deaths in patients with diabetes. Many drug trials have concentrated on blood glucose (hemoglobin A1c) reduction. This strategy, while reducing microvascular outcomes like nephropathy and neuropathy, has little or no ...
Prakash Deedwania, Tushar Acharya
openaire +3 more sources
Oral antiplatelet agents in cardiovascular disease
Vasa, 2019Abstract. Antiplatelet agents significantly reduce mortality and morbidity in ischemic heart disease, cerebrovascular disease and peripheral artery disease (PAD), and are therefore part of guideline-driven daily medical treatment in these patients. Due to its beneficial effects in the secondary prevention of atherothrombotic events, aspirin remains ...
Simon Panzer +3 more
openaire +3 more sources
Cardiovascular toxicity of molecularly targeted agents
European Journal of Cancer, 2009Over the last decade, molecularly targeted drugs have become established in oncology therapeutics and clinical research. While initially marketed as “cancer specific” agents with superior toxicity profiles to conventional anti-proliferative and DNA-damaging chemotherapy, it has become increasingly apparent that these drugs have numerous serious “on ...
Elizabeth Laureen Strevel +1 more
openaire +3 more sources
Urokinase-a Very Popular Cardiovascular Agent
Recent Patents on Cardiovascular Drug Discovery, 2008Urokinase (UK) [EC 3.4.99.26] is a serine protease that activates plasminogen to plasmin, which in turn degrades fibrin clots. Hence, UK finds its value as an important anti-thromboembolic drug. Plasmin has diverse physiological roles apart from its fibrinolytic role in the regulation of blood clotting.
Poluri Ellaiah +4 more
openaire +2 more sources
Therapeutic potential of chalcones as cardiovascular agents
Life Sciences, 2016Cardiovascular diseases are the leading cause of death affecting 17.3 million people across the globe and are estimated to affect 23.3 million people by year 2030. In recent years, about 7.3 million people died due to coronary heart disease, 9.4 million deaths due to high blood pressure and 6.2 million due to stroke, where obesity and atherosclerotic ...
Debarshi Kar Mahapatra +1 more
openaire +3 more sources
Cardiovascular Effects of Intravenous Anesthetic Agents [PDF]
, 1985 The most commonly used anesthetic agents of this kind are the barbiturates. The duration of action of these agents is tied to their fat solubility. Since the thiobarbiturates are more fat soluble (classified as ultra-short acting), they provide a surgical plane of anesthesia for less time than the short acting agents such as pentobarbital sodium.
openaire +1 more source
Novel Antiplatelet Agents in Cardiovascular Medicine
Current Treatment Options in Cardiovascular Medicine, 2015Dual antiplatelet therapy with aspirin and a P2Y12 receptor blocker, particularly clopidogrel, has been the standard of therapy for secondary prevention in patients with acute coronary syndromes and patients treated with percutaneous coronary intervention.
Fang Liu +4 more
openaire +3 more sources
Contrast Agents for Cardiovascular MRI
2008In the last two decades, magnetic resonance imaging (MRI) has revolutionized clinical cardiovascular imaging. Its major advantages over other noninvasive diagnostic modalities are its safety, operator-independent reproducibility, and multiplanar two-dimensional (2D) and three-dimensional (3D) imaging capability with high spatial and temporal resolution.
Frank J. Rybicki +4 more
openaire +2 more sources
Naturoceutical Agents in the Management of Cardiovascular Disease
American Journal of Cardiovascular Drugs, 2002During the past decade, complementary and alternative medicine (CAM) has grown in attractiveness to the Western public, and in recognition by practitioners of traditional medicine. The incorporation of effective CAM therapies into traditional practice is termed 'integrative medicine'. One form of CAM demonstrating exponential growth through mass public
openaire +3 more sources
Cardiovascular Effects of Hypoglycemic Agents in Diabetes Mellitus
Current Drug Safety, 2021Background: Despite substantial improvements over the years, diabetes mellitus is still associated with cardiovascular disease, heart failure, and excess mortality. Objective: The objective of this article is to examine existing data on the reduction of cardiovascular morbidity and mortality in diabetes.
openaire +4 more sources